Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Camrelizumab Plus Famitinib Shows Promise in Recurrent or Metastatic Cervical Cancer

November 29th 2023

The combination comprised of camrelizumab and famitinib showcased improved efficacy with a manageable safety profile vs camrelizumab monotherapy or investigator’s choice of chemotherapy in patients with recurrent or metastatic cervical cancer.

Nimotuzumab With Concurrent Chemoradiotherapy Shows Activity in Cervical Squamous Cell Carcinoma

November 28th 2023

Nimotuzumab given concurrently with chemoradiotherapy demonstrated efficacy and favorable tolerability in patients with locally advanced cervical squamous cell carcinoma, according to data from a randomized, controlled, open-label, multicenter study.

Retifanlimab Continues to Elicit Responses in Recurrent MSI-H or dMMR Endometrial Cancer

November 28th 2023

Retifanlimab-dlwr continued to elicit responses with acceptable tolerability in patients with recurrent microsatellite instability–high or mismatch–repair deficient endometrial cancer, according to final findings from cohort H of the phase 1 POD1UM-101 trial.

Cadonilimab Plus Chemo With or Without Bevacizumab Improves PFS in Recurrent or Metastatic Cervical Cancer

November 28th 2023

The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.

FDA Approves Nirogacestat for Desmoid Tumors

November 27th 2023

The FDA has approved nirogacestat (Ogsiveo) for adult patients with progressing desmoid tumors who require systemic treatment.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Improves PFS in R/R Multiple Myeloma

November 27th 2023

Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial.

Sugemalimab Receives Approval in China for Relapsed/Refractory Extranodal NK/T-cell Lymphoma

November 22nd 2023

The National Medical Products Administration of China has approved sugemalimab for use in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

SCO-101 Plus FOLFIRI Prolongs Survival in Metastatic Colorectal Cancer

November 22nd 2023

SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) prolonged survival in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.

MRT-2359 Shows Favorable Tolerability in Heavily Pretreated MYC-Driven Solid Tumors

November 21st 2023

MRT-2359 had acceptable tolerability with a favorable pharmacokinetic and pharmacodynamic profile in heavily pretreated patients with MYC-driven solid tumors, including lung cancer and high-grade neuroendocrine cancer.

Volrustomig Demonstrates Activity in Treatment-Naive Advanced ccRCC

November 16th 2023

Volrustomig demonstrated efficacy when used as frontline treatment in patients with clear cell renal cell carcinoma with a toxicity profile that is consistent with dual checkpoint inhibition.

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

November 16th 2023

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Durvalumab With Concurrent Chemoradiation Misses PFS End Point in Unresectable Stage III NSCLC

November 14th 2023

Concurrent administration of durvalumab and platinum-based chemoradiation failed to significantly improve progression-free survival over chemoradiation alone in patients with unresectable stage III non–small cell lung cancer, missing the primary end point of the phase 3 PACIFIC-2 trial.

Momelotinib Approaches EU Approval for Myelofibrosis With Anemia

November 14th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of momelotinib for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anemia with primary myelofibrosis, post–polycythemia vera myelofibrosis, or post–essential thrombocytopenia myelofibrosis who have not been exposed to a JAK inhibitor or who had received prior ruxolitinib.

CHMP Recommends Adagrasib for Pretreated KRAS G12C+ Advanced NSCLC

November 14th 2023

After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.

Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma

November 13th 2023

Bayer has announced the intention to voluntarily withdraw the new drug application for copanlisib in adult patients with relapsed follicular lymphoma who have previously received at least 2 prior systemic treatments.

Frontline Pembrolizumab Plus Chemo Approaches EU Approval for Biliary Tract Cancer

November 10th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) combined with gemcitabine and cisplatin in the frontline treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer

PDS0101-Based Triplet Provides Survival Benefit in HPV16+ Cancers

November 9th 2023

The combination of PDS0101, PDS0301 (formerly M-9241), and bintrafusp alfa, an investigational immune checkpoint inhibitor extended survival in patients with advanced human papillomavirus 16–positive cancers, according to final data from a phase 2 trial (NCT04287868) led by the National Cancer Institute.

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

November 9th 2023

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

FDA Grants Priority Review to Liso-Cel for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

November 9th 2023

The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.

Neoadjuvant Inetetamab Combo Shows Efficacy, Tolerability in Locally Advanced HER2+ Breast Cancer

November 8th 2023

The combination of inetetamab, pertuzumab, paclitaxel, and carboplatin elicited responses with an acceptable safety profile when administered as neoadjuvant treatment in patients with locally advanced HER2-positive breast cancer.